Lang Li

Lang Li

Auto-generated profile, based on publicly available information

Lang Li

Department of Hematology, Jinhua Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, 438 West Shuangxi Road, Jinhua 321017, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
LLLang Li
Lang Li
YZYing Zhu
Ying Zhu
CZChenchong Zhao
Chenchong Zhao
YTYinuo Tangwu
Yinuo Tangwu
LHLvyuan He
Lvyuan He
GLGaochen Lan
Gaochen Lan
Background: Lung cancer oncogenesis involves interactions between immune cells and inflammatory cytokines. However, their causal relationships and mediating mechanism remain unclear. Methods: Using a mediating Mendelian randomization (MR) approach, we analyzed genome‐wide association study (GWAS) data for 731 immune‐cellular phenotypes, 41 cytokines, and eight related lung cancer phenotypes. Results: BAFF-R expression in IgD + CD24 + B cells was positively associated with lung adenocarcinoma (LUAD) risk (odds ratio [OR], 1.0168 [95% confidence interval [CI], 1.0006–1.0332]), mediated by macrophage migration inhibition factor (MIF) with a mediation proportion of 14.2% (95% CI, 0.00007–0.0046). CD39 expression on secreting CD4 Tregs was related to an increased risk of small‐cell lung cancer (SCLC) (OR, 1.0306 [95% CI, 1.0006–1.0616]), mediated by interleukin (IL)‐2 and IL‐6 with mediation proportions of 8.43% (95% CI, 0.00005−0.005) and 5.1% (95% CI, 0.00006–0.003), respectively. CD28 expression on CD39 + CD4 + T cells was positively correlated to lung squamous cell carcinoma (LUSC) risk (OR, 1.0335 [95% CI, 1.009–1.0586]), inversely mediated by IL‐16 (95% CI, −0.01 to −0.0003). Conclusions: These findings reveal the associations between immune cells, inflammatory cytokines, and lung cancer risk, providing insights into cancer diagnosis and treatment.

31 March 2023
Verified
Other
Open access
WWWeili Wang
Weili Wang
LHLei Huang
Lei Huang
JJJian-Yue Jin
Jian-Yue Jin
SJShruti Jolly
Shruti Jolly
YZYong Zang
Yong Zang
FKFeng-Ming Kong
Feng-Ming Kong
Detail of Prospective Clinical Trials.

31 March 2023
Verified
Other
Open access
WWWeili Wang
Weili Wang
LHLei Huang
Lei Huang
JJJian-Yue Jin
Jian-Yue Jin
SJShruti Jolly
Shruti Jolly
YZYong Zang
Yong Zang
FKFeng-Ming Kong
Feng-Ming Kong
Detail of Prospective Clinical Trials.

31 March 2023
Verified
Other
Open access
WWWeili Wang
Weili Wang
LHLei Huang
Lei Huang
JJJian-Yue Jin
Jian-Yue Jin
SJShruti Jolly
Shruti Jolly
YZYong Zang
Yong Zang
FKFeng-Ming Kong
Feng-Ming Kong

31 March 2023
Verified
Other
Open access
WWWeili Wang
Weili Wang
LHLei Huang
Lei Huang
JJJian-Yue Jin
Jian-Yue Jin
SJShruti Jolly
Shruti Jolly
YZYong Zang
Yong Zang
FKFeng-Ming Kong
Feng-Ming Kong